Genelux Corporation (GNLX)
NASDAQ: GNLX · Real-Time Price · USD
2.870
-0.030 (-1.03%)
At close: Jun 26, 2026, 4:00 PM EDT
3.130
+0.260 (9.06%)
After-hours: Jun 26, 2026, 7:54 PM EDT
Genelux Earnings Call Transcripts
Fiscal Year 2026
-
The meeting covered the election of a director and auditor ratification, with both proposals approved. No shareholder questions were received, and final voting results will be filed with the SEC.
-
The discussion highlighted Olvi-Vec's potential as a backbone therapy in oncology, showing strong efficacy in platinum-resistant ovarian cancer and promising early results in lung cancer. The company is preparing for commercial launch, expanding indications, and expects pivotal data later this year.
Fiscal Year 2025
-
The meeting confirmed a quorum, elected two directors through 2028, and ratified the independent auditor for 2025. No shareholder questions were received, and a business update is planned for later in the fall.